Altimmune Statistics
Total Valuation
Altimmune has a market cap or net worth of $549.91 million. The enterprise value is $401.67 million.
Important Dates
The next estimated earnings date is Thursday, August 7, 2025, before market open.
| Earnings Date | Aug 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Altimmune has 81.11 million shares outstanding. The number of shares has increased by 23.58% in one year.
| Current Share Class | 81.11M |
| Shares Outstanding | 81.11M |
| Shares Change (YoY) | +23.58% |
| Shares Change (QoQ) | +6.02% |
| Owned by Insiders (%) | 0.84% |
| Owned by Institutions (%) | 47.50% |
| Float | 80.43M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 27,495.26 |
| Forward PS | n/a |
| PB Ratio | 3.71 |
| P/TBV Ratio | 3.87 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 20,083.31 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 15.85, with a Debt / Equity ratio of 0.01.
| Current Ratio | 15.85 |
| Quick Ratio | 15.54 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -10,910.33 |
Financial Efficiency
Return on equity (ROE) is -57.28% and return on invested capital (ROIC) is -38.69%.
| Return on Equity (ROE) | -57.28% |
| Return on Assets (ROA) | -35.51% |
| Return on Invested Capital (ROIC) | -38.69% |
| Return on Capital Employed (ROCE) | -66.59% |
| Revenue Per Employee | $339 |
| Profits Per Employee | -$1.53M |
| Employee Count | 59 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -681,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +14.53% in the last 52 weeks. The beta is 0.57, so Altimmune's price volatility has been lower than the market average.
| Beta (5Y) | 0.57 |
| 52-Week Price Change | +14.53% |
| 50-Day Moving Average | 5.47 |
| 200-Day Moving Average | 6.56 |
| Relative Strength Index (RSI) | 63.54 |
| Average Volume (20 Days) | 3,475,445 |
Short Selling Information
The latest short interest is 21.98 million, so 27.10% of the outstanding shares have been sold short.
| Short Interest | 21.98M |
| Short Previous Month | 22.67M |
| Short % of Shares Out | 27.10% |
| Short % of Float | 27.33% |
| Short Ratio (days to cover) | 9.11 |
Income Statement
In the last 12 months, Altimmune had revenue of $20,000 and -$90.24 million in losses. Loss per share was -$1.25.
| Revenue | 20,000 |
| Gross Profit | -76.55M |
| Operating Income | -98.19M |
| Pretax Income | -101.35M |
| Net Income | -90.24M |
| EBITDA | -98.03M |
| EBIT | -98.19M |
| Loss Per Share | -$1.25 |
Full Income StatementBalance Sheet
The company has $149.83 million in cash and $1.59 million in debt, giving a net cash position of $148.24 million or $1.83 per share.
| Cash & Cash Equivalents | 149.83M |
| Total Debt | 1.59M |
| Net Cash | 148.24M |
| Net Cash Per Share | $1.83 |
| Equity (Book Value) | 142.16M |
| Book Value Per Share | 1.83 |
| Working Capital | 145.46M |
Full Balance SheetCash Flow
| Operating Cash Flow | -80.33M |
| Capital Expenditures | n/a |
| Free Cash Flow | -80.33M |
| FCF Per Share | -$0.99 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -490,965.00% |
| Pretax Margin | -454,605.00% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Altimmune does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -23.58% |
| Shareholder Yield | -23.58% |
| Earnings Yield | -16.41% |
| FCF Yield | -14.61% |
Dividend DetailsAnalyst Forecast
The average price target for Altimmune is $21.00, which is 209.74% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $21.00 |
| Price Target Difference | 209.74% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | 638.06% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on September 14, 2018. It was a reverse split with a ratio of 0.0333333:1.
| Last Split Date | Sep 14, 2018 |
| Split Type | Reverse |
| Split Ratio | 0.0333333:1 |
Scores
Altimmune has an Altman Z-Score of 13.87 and a Piotroski F-Score of 1.
| Altman Z-Score | 13.87 |
| Piotroski F-Score | 1 |